Advances in the management of recurrent endometrial cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 2, 2015, Pages 206-212

  Bradford, Leslie S ^a   Rauh Hain, Jose Alejandro ^a   Schorge, John ^a   Birrer, Michael J ^b   Dizon, Don S ^b  

^a Departments of Obstetrics Gynecology   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

chemoradiation; chemotherapy; endometrial cancer; metastatic disease; prognosis; radiation therapy; surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE; MEGESTROL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TOPOTECAN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CANCER; HUMAN; META ANALYSIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PELVIS EXENTERATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; ENDOMETRIAL NEOPLASMS; FEMALE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 84926418711     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31829a2974     Document Type: Review

References (63)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141-1149.
3. Amant F, Mansoor RM, Creutzberg CL. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2012;119(suppl 2): S110-S117.
4. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218e1-218e6.
5. Boruta DM II, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115:142-153.
6. Olawaiye AB, Boruta DM II. Management of women with clear cell endometrial cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277-283.
7. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642-646.
8. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14:30-38.
9. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93-108.
10. Greer BE, Koh WJ, Abu-Rustum N, et al. Uterine neoplasms. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:498-531.
11. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-262.
12. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466-478.
13. Moore R, Miller C, Horan T, et al. A novel marker for the management of women diagnosed with endometrial adenocarcinoma of the uterus. Presented at the 42nd Annual Meeting on Womens Cancer, Austin, TX; 2013.
14. Del Carmen MG, Boruta DM II, Schorge JO. Recurrent endometrial cancer. Clin Obstet Gynecol. 2011;54:266-277.
15. Randall ME, Filliaci VL, Muss H, et al. Randomized phase III trial of whole abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36-44.
16. Keys HM, Roberts JA, Bruneto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;92:744-751.
17. Creutzberg CL, van Putten WL, Koper PC, et al. PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201-209.
18. Dunton CJ, Balsara G, McFarland M, et al. Uterine papillary serous carcinoma: A review. Obstet Gynecol Surv. 1991;46:97-102.
19. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404-1411.
20. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81: e631-e638.
21. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143.
22. Huh WK, Straughn JM Jr, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience. Int J Gynecol Cancer. 2007;17:886-889.
23. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of complete cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20: 1248-1259.
24. Morris M, Alvarez RD, Kinney WK, et al. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol. 1996;60:288-291.
25. Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75:99-102.
26. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis. Gynecol Oncol. 2010;118:14-18.
27. Khoury-Collado F, Einstein MH, Bochner BH, et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol. 2012;124:42-47.
28. Arellano RS, Flanders VL, Lee SI, et al. Imaging-guided percutaneous radiofrequency ablation of retroperitoneal metastatic disease in patients with gynecologic malignancies: clinical experience with eight patients. Am J Roentgenol. 2010;194:1635-1638.
29. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma-ma: A Gynecologic Oncology Group Study. J Clin Oncol. 2001;19:364-367.
30. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol. 2002;14:67-73.
31. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;92:10-14.
32. Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2000;78:212-216.
33. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;92:4-9.
34. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409-420.
35. Fleming GF, Brunetto VL, Celia D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
36. Miller D, Filiaci V, Fleming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2012;125:771.
37. Homesley HD, Blessing JA, Sorosky J, et al. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2005;98:294-298.
38. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2003;88:277-281.
39. Moore DH, Blessing JA, Dunton C, et al. Evaluation of dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999;75:473-475.
40. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2002;20:2360-2364.
41. Miller DS, Blessing JA, Lentz SS, et al. Evaluation of topotecan in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2002;87: 247-251.
42. Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2006;103:523-526.
43. Garcia A, Blessing J, Nolte S, et al. A phase II evaluation of weekly docetaxel (NSC #628503) in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2008;111:22-26.
44. Dizon DS, Blessing JA, McMeekin S, et al. Phase II trial of Ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129P. J Clin Oncol. 2009;27:3104-3108.
45. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27: 2278-2287.
46. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13:3109-3114.
47. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29: 3278-3285.
48. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116: 5415-5419.
49. Naing A, Aghajanian C, Raymond E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012;107: 1093-1099.
50. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
51. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2011;29: 2259-2265.
52. OMalley D, McCann G, Fowler J, et al. A phase II evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced stage endometrial carcinoma. Presented at the 42nd Annual Meeting on Womens Cancer, Austin, TX; 2013.
53. McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group Study. Gynecol Oncol. 2007;105:508-516.
54. Fleming GF, Morgan R, Wang L, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II consortium (abstract). J Clin Oncol. 2010;28(suppl), abstract number 5038.
55. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117:37-40.
56. Zhang Y, Banerjee S, Wang Z, et al. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappa B in pancreatic cancer. Cancer Res. 2006;66:1025-1032.
57. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277:301-308.
58. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26:4319-4325.
59. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116:15-20.
60. Konecny GE, Venkatesan N, Yang G, et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98:1076-1084.
61. El-Sahwi K, Bellone S, Cocco E, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010;102:134-143.
62. Coleman R, Sill M, Thaker P, et al. A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. Presented at the 42nd Annual Meeting on Womens Cancer, Austin, TX; 2013.
63. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5:203-220.